antagonist radioligands ͉ tumor targeting ͉ peptide hormones ͉ neuropeptides ͉ receptor internalization P eptide receptor targeting in vivo is a successful method to image and treat various types of cancers (1). The best example is somatostatin receptor targeting with 111 In-, 90 Y-, or 177 Lu-labeled somatostatin radioligands that are injected into the patients intravenously and accumulate in their somatostatin receptor-expressing tumors. For this purpose, agonists have been selected. The rationale is that agonists, after high-affinity binding to the receptor, usually trigger internalization of the ligandreceptor complex (2). This process of internalization is the basis for an efficient accumulation of the radioligand in a cell over time (1, (3) (4) (5) , and it has been considered a crucial step in the process of in vivo receptor targeting with radiolabeled peptides (4-6). Recently, a highly significant correlation between the rate of ligand internalization in vitro into AR42J cells expressing somatostatin receptor subtype 2 (sst 2 ) and the in vivo uptake in the sst 2 -expressing rat tumor model has been reported
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eptide receptor targeting in vivo is a successful method to image and treat various types of cancers (1) . The best example is somatostatin receptor targeting with 111 In-, 90 Y-, or 177 Lu-labeled somatostatin radioligands that are injected into the patients intravenously and accumulate in their somatostatin receptor-expressing tumors. For this purpose, agonists have been selected. The rationale is that agonists, after high-affinity binding to the receptor, usually trigger internalization of the ligandreceptor complex (2) . This process of internalization is the basis for an efficient accumulation of the radioligand in a cell over time (1, (3) (4) (5) , and it has been considered a crucial step in the process of in vivo receptor targeting with radiolabeled peptides (4) (5) (6) . Recently, a highly significant correlation between the rate of ligand internalization in vitro into AR42J cells expressing somatostatin receptor subtype 2 (sst 2 ) and the in vivo uptake in the sst 2 -expressing rat tumor model has been reported (7) . Therefore, when novel analogs are being designed for receptor targeting, their internalization properties are particularly thoroughly investigated (3) .
Curiously, not much is known about the usefulness, for in vivo targeting of cancer, of high binding-affinity compounds lacking the ability to trigger receptor internalization. In this respect, little is known about antagonists, which, with a few exceptions (8) (9) (10) (11) , do not internalize (8, 12, 13) , and one could therefore expect them not to be of particular interest as radioligands for receptor targeting. However, antagonists may have characteristics other than those related to internalization that may make their radiolabeled derivatives suitable tools for in vivo receptor targeting. Most relevant is the in vitro evidence that, in certain circumstances, antagonist radioligands may label a higher number of receptor-binding sites than agonist radioligands (14, 15) .
The aim of the present study was to investigate to which extent somatostatin antagonist and agonist radioligands, with similar binding affinities for somatostatin receptors, differ in their in vivo tumor-targeting properties. The best clinically established system for in vivo tumor targeting with radiolabeled peptides (1) is based on the somatostatin receptor, and a particularly large number of excellent radioligands have been developed for that purpose, all derived from somatostatin agonists (16) . The first part of the present study deals with somatostatin receptor subtype 3 (sst 3 ). First, sst 3 is characterized by very efficient internalization properties (17) . Second, recently, sst 3 -selective antagonists with high binding affinity but without triggering receptor internalization have been described (18) . Their radiolabeled derivatives may be used as antagonist radioligands in case the high affinity-binding and antagonistic properties are retained after conjugation with a chelator [e.g., 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)] and 111 In-complexation. Third, well characterized radiolabeled agonists, which can label sst 3 receptors in vitro and in vivo, have recently been described (19) (20) (21) 111 In-labeled form as a negative control for sst 3 -expressing tissues in the biodistribution assays, shows high sst 2 but no sst 3 affinity ( Table 1) .
The compounds were evaluated for their effect on forskolinstimulated cAMP accumulation in CCL39 cells stably expressing sst 3 (Table 1) . SS-28 and nat In-DOTA-NOC, used as controls, act as agonists; they potently inhibit forskolin-stimulated cAMP accumulation by Ͼ77% and 58%, respectively, at a peptide concentration of 100 nM. sst 3 -ODN-8 and its two derivatives given alone do not inhibit forskolin-stimulated cAMP accumulation up to 10 M. However, the agonistic effect of SS-28 can be competitively antagonized with a fixed concentration of 1 M each of the sst 3 -ODN-8 derivatives applied individually. Fig. 1B illustrates the antagonistic properties of the sst 3 -ODN-8 derivatives.
The antagonistic property of DOTA-sst 3 -ODN-8 and its derivatives was also confirmed in an immunofluorescence internalization assay (3) with HEK293 cells stably expressing sst 3 ( Table 1) . Fig. 1C illustrates that, although the control agonists SS-28 and nat In-DOTA-NOC can induce sst 3 internalization, the DOTA-sst 3 -ODN-8 analogs have no effect when given alone, even at a concentration of 10 M. Moreover, they prevent sst 3 internalization induced by SS-28 (Fig. 1C) or by the agonist nat In-DOTA-NOC.
Furthermore, Fig. 1D shows a Scatchard analysis in HEK-sst 3 cells comparing the B max for the agonist 111 In-DOTA-NOC (68 Ϯ 9 pM) with that of the antagonist 111 In-DOTA-sst 3 -ODN-8 (5,180 Ϯ 70 pM). The antagonist labels 76 times more sst 3 sites in cultured HEK-sst 3 cells than the agonist.
In Tables 2 and 3 , the in vivo biodistribution of the antagonist 111 In-DOTA-sst 3 -ODN-8 is reported in nude mice bearing the sst 3 -expressing tumor (Table 2 ) and compared with that of the agonist 111 In-DOTA-NOC (Table 3 ). Of note is the accumulation of the radiolabeled antagonist in the tumor, which peaks at 1 h [Ͼ60% injected activity per gram of tissue (IA͞g) uptake] and remains very high at 4 h (50%IA͞g), at 24 h (Ͼ30%IA͞g) and even at 72 h (Ͼ10%IA͞g). The pituitary, an organ known to express various sst, including sst 3 (17) , is also labeled with the antagonist 111 In-DOTA-sst 3 -ODN-8 ( Table 2) . A blocking experiment performed in separate mice by adding 1,000 times excess of sst 3 -ODN-8 together with the radioligand documents that the majority of the labeling in the sst 3 -expressing tumor and pituitary represents binding to specific somatostatin receptors. The blocking agent did not affect radioactivity uptake in the kidneys and blood, indicating that this uptake is not receptormediated (Table 2 ). For comparison, the accumulation of radioactivity in the sst 3 -expressing tumors by using the agonist 111 In-DOTA-NOC is considerably less than by using the antagonist 111 In-DOTA-sst 3 -ODN-8 and amounts to Ϸ7%IA͞g at 4 h and decreases at 24 h ( Table 3 ). The calculated tumor͞tissue ratios, representing important parameters to evaluate the quality of a targeting agent (16) , are considerably higher with 111 In-DOTA-sst 3 -ODN-8 than with 111 In-DOTA-NOC, especially for the tumor͞blood and tumor͞muscle ratios at 4 and 24 h. Established sst 2 -expressing organs, such as the stomach, adrenals, or pancreas, show a blockable accumulation of 111 In-DOTA-NOC (Table 3) , whereas they show no significant accumulation of 111 In-DOTA-sst 3 -ODN-8 ( Table 2) . As a negative control, labeling of the sst 3 -expressing tumor with a specific sst 2 agonist radioligand, 111 In-DTPA-TATE (22) , is found to be negligible (Table 3 ). The high uptake of 111 In-DOTA-NOC and 111 In-DTPA-TATE in the pituitary reflects the high expression of sst 2 in this organ. Fig. 2 shows scans taken at 30 min and 4 h of animals bearing sst 3 -expressing tumors in one flank and, as control, sst 2 -expressing tumors in the other flank. Mice injected with the sst 3 antagonist 111 In-DOTA-sst 3 -ODN-8 showed a massive uptake in the sst 3 -but not the sst 2 -expressing tumor, whereas those injected with the sst 2 ͞sst 3 agonist 111 In-DOTA-NOC showed a weak uptake in both tumors.
Similarly, we investigated the sst 2 receptor system with sst 2 -transfected HEK293 and CCL39 cells in vitro or HEK293 cells transplanted in animals, to expand the above sst 3 study. We chose to conjugate the established sst 2 -ANT (23) with DOTA, namely DOTA-[4-NO 2 -Phe-c(DCys-Tyr-DTrp-Lys-Thr-Cys)-DTyr-NH 2 ] (DOTA-sst 2 -ANT). sst 2 -ANT and unlabeled or Inlabeled DOTA-sst 2 -ANT have high binding affinity and selectivity for sst 2 (Table 1 ). Both the In-labeled and unlabeled DOTA-sst 2 -ANT are sst 2 -antagonists in the cAMP assay; although inactive at 10 M concentration in the absence of SS-28, they reverse completely the 100 nM SS-28-induced inhibition of cAMP formation triggered by 30 M forskolin in CCL-sst 2 cells. Further, they also act as antagonists in the immunofluorescence internalization assay, because they do not induce internalization of the sst 2 receptor up to 10,000 nM but inhibit completely at 1,000 nM the internalization induced by potent somatostatin agonists such as DTPA-TATE (Fig. 3) . The tissue biodistribution after 111 In-DOTA-sst 2 -ANT injection in mice reveals a high but also long-lasting tumor uptake in sst 2 tumor-bearing animals ( Table 4) . It is impressive to see that 4-and 24-h values of tumor uptake are twice the ones obtained with the highly potent sst 2 agonist 111 In-DTPA-TATE given under the same conditions. As proof of specificity, uptake in the tumor is massively blocked by excess DOTA-sst 2 -ANT (Table 4) . Moreover, Scatchard analysis in HEK-sst 2 cells identifies more sites labeled with the radiolabeled antagonist (B max ϭ 354 Ϯ 14 pM) than with the agonist (B max ϭ 23 Ϯ 1.0 pM).
Discussion
Agonists have been used exclusively as radioligands in the past decade for the development and implementation of peptide receptor targeting of tumors in vivo, because such radioligands are readily internalized together with the receptor, permitting an active accumulation of radioactivity in the tumor cells (1, (3) (4) (5) . The present study may build the foundation for a change of paradigm in this respect. Indeed, it shows, unexpectedly, that adequately labeled sst 2 and sst 3 antagonists, even though they do not internalize, may be useful radioligands to target tumors in vivo. More importantly, it also shows that antagonists may be even better candidates to target tumors than agonists with comparable binding characteristics.
In the in vivo model of an sst 3 -expressing tumor, we have compared the biodistribution of the sst 3 antagonist, 111 In-DOTAsst 3 -ODN-8, with that of an established agonist, 111 In-DOTA-NOC (19) (20) (21) .
nat In-DOTA-NOC has high binding affinity to sst 3 receptors in vitro (19) and efficiently triggers the sst 3 internalization into HEK-sst 3 cells. The DOTA-linked sst 3 -ODN-8 antagonist, with or without indium, also shows a comparably high sst 3 -binding affinity but, differently from nat In-DOTA-NOC, it cannot trigger sst 3 internalization into HEK-sst 3 cells. Therefore, although one can expect to see a specific in vivo uptake of 111 In-DOTA-NOC in sst 3 -expressing tumors, it is unexpected, based on current knowledge (1, (3) (4) (5) , to see such a high uptake with 111 In-DOTA-sst 3 -ODN-8. The uptake in the tumors and in the sst 3 -expressing pituitary is specific in both cases, because it can be specifically blocked by the corresponding cold peptide, indicating a somatostatin receptor-mediated process.
One of the most impressive findings is that the amount of uptake of the antagonist radioligand is particularly high in these tumors: 60%IA͞g uptake has indeed never been achieved by any somatostatin receptor agonist ligand, not even by those developed most recently (19, 21) . Not only is the uptake at the peak time point very high, but also the long-lasting accumulation of the antagonist radioligand up to 72 h after injection is a remarkable result and represents a considerable advantage over labeling with established agonists. Of crucial importance for potential clinical use are the high tumor͞tissue ratios obtained with the radiolabeled antagonist.
The same observation of a much better labeling is obtained in HEK-sst 2 tumors with the sst 2 antagonist 111 In-DOTA-sst 2 -ANT. Knowing of the outstanding targeting abilities of 111 In- 
DTPA-TATE (22)
, it is striking to see that the in vivo labeling at 4 and 24 h for the sst 2 antagonist is twice as high, despite the fact that the antagonist is not internalized into the tumor cells and that its sst 2 -binding affinity is lower than for the agonist. Explanations for these excellent in vivo targeting properties of antagonists may be found, at least in part, in previous in vitro studies dealing with other G protein-coupled receptors. Indeed, a higher number of 5-HT 2A (15) or corticotropin releasing factor (CRF) receptors (14) were reported to be labeled in vitro with radiolabeled antagonists than with agonists, probably reflecting a difference in the receptor interaction with the G proteins (14) . Similar conclusions can be drawn for sst 2 and sst 3 receptors labeled with antagonists, as shown in our Scatchard data. It appears, therefore, that, in an in vivo situation, an agonist that triggers a strong internalization but binds to a limited number of high-affinity receptors is a less-efficient targeting agent than an antagonist lacking internalization capabilities but binding to a larger variety of receptor conformations.
The long-lasting in vivo labeling of antagonists, in particular 111 In-DOTA-sst 3 -ODN-8, may be brought in association to earlier findings by Wynn et al. (13) with gonadotropin-releasing hormone (GnRH) analogs. Although in vitro quantitative autoradiography did not detect any significant internalization at the electron-microscopic level of a GnRH antagonist during in vitro incubation for up to 120 min, in vivo cellular accumulation and binding of this antagonist to the pituitary GnRH receptor increased slowly during the 10 h after i.v. injection (13) . These data were interpreted as reflecting the slow dissociation of the bound antagonist, with a persistence of specific binding up to 8 days after injection (13) but possibly also a delayed and slow internalization of the antagonist occurring 4-36 h after injection (13) . Not to be ignored in this regard is that antagonists are also more chemically stable and more hydrophobic than agonists, resulting in longer duration of action and possible stabilization in the lipid-rich environment of the receptors.
What are the consequences of the present data for in vivo targeting of human cancers? First, after safety and efficacy evaluation in humans, radiolabeled DOTA-sst 3 -ODN-8 should be evaluated in patients with sst 3 -expressing tumors, such as inactive pituitary adenomas or pheochromocytomas (24, 25) . Radiolabeled DOTA-sst 2 -ANT should be studied in patients with sst 2 -expressing tumors, consisting of a majority of neuroendocrine tumors. Then, it will be necessary to know whether the proposed change of paradigm can be generalized to other peptide receptor systems that are currently involved in peptide receptor targeting, including cholecystokinin, gastrin-releasing peptide, vasoactive intestinal peptide, neurotensin, and neuropeptide Y receptors (1) . The answer to this question represents a long-term project for the nuclear oncology͞molecular imaging community, requiring adequate tumor models, in vitro testing methods, and most importantly, adequate and potent antagonists as radioligands for the respective receptors. For the moment, peptidic antagonists are not available for every peptide receptor of interest and therefore need to be developed. The present results with 111 In-DOTA-sst 3 -ODN- 8 and 111 In-DOTAsst 2 -ANT, two radiolabeled peptide antagonists ready for nuclear medicine investigations, indicate the importance of developing such antagonist peptides. If the present observation can be confirmed for other receptors, the use of potent radiolabeled antagonists for in vivo tumor targeting may considerably improve the sensitivity of diagnostic procedures and the efficacy of receptor-mediated radiotherapy.
Materials and Methods
Peptides. Peptides were synthesized as described (18, 19) . Radioactive or nonradioactive metals were chelated to the DOTAcoupled sst 3 -ODN-8, DOTA-NOC, DOTA-sst 2 -ANT, and DTPA-TATE, as described (21) . The structure of DOTA-sst 3 -ODN-8 is shown in Fig. 1 A. Cell Culture. The HEK293 cell lines (HEK-sst 2 , HEK-sst 3 ) and the CCL39 cell lines (CCL-sst 2 , CCL-sst 3 ) stably expressing the human sst 2 or sst 3 were grown as described (3, 26) . sst1, sst2, sst3, sst4, and sst5 Receptor Binding in Vitro. The sst 1 -, sst 2 -, sst 3 -, sst 4 -, and sst 5 -binding affinities of various compounds listed in Table 1 were measured by using in vitro receptor autoradiography, as described (26) .
Saturation-binding experiments for 111/nat In-DOTA-sst 2 -ANT and 111/nat DTPA-TATE or 111/nat In-DOTA-sst 3 -ODN-8 and 111/nat In-DOTA-NOC were performed on HEK-sst 2 or -sst 3 cells, respectively, at 4°C by using increasing concentrations of the 111/nat In-labeled peptide ranging from 0.1 to 1,000 nM, as described (27) . One micromolar cold peptide was used to quantify nonspecific binding. B max was calculated for each radioligand from Scatchard plotting of the obtained data by using Origin 5.0 software (Microcal Software, Northampton, MA).
Adenylate Cyclase Activity. Forskolin-stimulated cAMP accumulation was determined in CCL-sst 2 and -sst 3 cells by using a commercially available cAMP scintillation proximity assay, as described (18) . sst2 and sst3 Receptor Internalization. Immunofluorescence microscopy-based internalization assay for sst 2 and sst 3 was performed as described (3) . For sst 3 immunocytochemistry, the commercially available sst 3 -specific antibody SS-850 (Gramsch Labora- In-DOTA-NOC. Each mouse was bearing two tumors, an sst3-expressing tumor and, as control, an sst 2-expressing tumor. Mice were placed directly on one head of a two-headed gamma-camera system (PRISM 2000, Philips, Eindhoven, The Netherlands) equipped with medium-energy collimators (acquisition time, 10 min per time point). Strong uptake is seen with the antagonist radioligand in the sst 3-expressing tumor exclusively, whereas weak uptake was found in both tumors with the sst 2͞sst3 agonist. tories, Schwabenhausen, Germany) was used (3). For sst 2 immunocytochemistry, the sst 2 -specific antibody SS-800 (Gramsch Laboratories) or the R2-88 antibody (A. Schonbrunn, Universtiy of Texas Health Science Center, Houston, TX) were used, with equivalent results, as reported (3, 28) . HEK-sst 2 and -sst 3 cells were treated with the sst 2 or sst 3 agonists, respectively, at a concentration of 100 nM, or with agonists at a concentration of 100 nM in the presence of an excess of antagonists (100 times the concentration of the agonist) or with antagonists alone at a concentration of 10 M and processed for immunofluorescence microscopy (3).
HEK-sst2 and -sst3 Cell Implantation in Nude Mice. Animals were kept, treated, and cared for in compliance with the guidelines of the Swiss regulations (approval 789). Athymic female nude mice were implanted s.c. with 10-12 million HEK-sst 2 and -sst 3 cells, respectively, freshly suspended in sterile PBS. Ten to fourteen days after inoculation, the mice showed solid palpable tumor masses (tumor weights, 60-150 mg) and were used for the in vivo biodistribution experiments.
Confirmation that the transfected tumors were indeed expressing solely sst 2 or sst 3 , respectively, was obtained in resected tumor samples tested in vitro with somatostatin receptor autoradiography by using subtype selective ligands (24) .
In Vivo Biodistribution of 111 In-Labeled Antagonists and Agonists.
Mice were injected into a tail vein with 10 pmol 111 Inradiolabeled peptide (Ϸ0.15-0.2 MBq) in 0.1 ml of NaCl solution (0.9%, with 0.1% BSA). To determine the nonspecific uptake of the radiolabeled peptides, mice were injected with 49 nmol sst 3 -ODN-8 or nat In-DOTA-NOC (sst 3 study) or 20 nmol DOTA-sst 2 -ANT (sst 2 study) in 0.05 ml of NaCl solution (0.9%) as a coinjection with the radioligand.
To study the biodistribution of 111 In-DOTA-sst 3 -ODN-8, mice were killed at 0.25 h, 0.5 h, 1 h, 4 h, 24 h, or 72 h postinjection. For the biodistribution study of 111 In-DOTA-NOC or 111 In-DOTA-sst 2 -ANT, mice were killed at 0.5 h, 4 h, or 24 h postinjection. The biodistribution of 111 In-DTPA-TATE was studied at 0.5 h or 4 h after injection. The organs of interest were collected, blotted dried, and weighed; their radioactivity was measured, and the %IA͞g was calculated.
